StreetInsider.com News Articles

Form 4 MiNK Therapeutics, Inc. For: Oct 11 Filed by: Buell Jennifer

Wed, 14 Oct 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20261014/27186679.html

Form 144 MiNK Therapeutics, Inc. Filed by: Buell Jennifer

Tue, 13 Oct 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20261013/27177930.html

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

Fri, 02 Oct 2026 09:00:00 -0400

agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastases
Native and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

Fri, 02 Oct 2026 09:00:00 -0400

agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastases
Native and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment

MiNK Therapeutics joins ARPA-H's $87M room-temperature cell therapy program

Wed, 30 Sep 2026 07:58:19 -0400

MiNK Therapeutics, Inc. (NASDAQ: INKT) announced that its clinical-stage agenT-797 iNKT cell therapy platform has been selected as a therapeutic cell system within a team funded by the Advanced Research Projects Agency for Health (ARPA-H) to develop room-temperature storage technologies for cell therapies.

The selection is part of ARPA-H's BioStabilization Systems (BoSS) program, a four-year initiative with up to $87 million in committed funding. The program seeks to move cell therapy storage from cryogenic temperatures near -196°C to room temperature near 21°C, reducing dependence on cold-chain infrastructure.

MiNK is a member of the Reversible Ambient Biostabilization (RAB) team led by The Charles

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Wed, 30 Sep 2026 07:57:00 -0400

Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature

ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its clinical-stage agenT-797 iNKT platform has been selected as

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Wed, 30 Sep 2026 07:57:00 -0400

Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature

ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines

Form S-8 MiNK Therapeutics, Inc.

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921925.html

Form S-8 MiNK Therapeutics, Inc.

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921925.html

Form 10-Q MiNK Therapeutics, Inc. For: Jun 30

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921861.html

Form 10-Q MiNK Therapeutics, Inc. For: Jun 30

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921861.html

Form 8-K MiNK Therapeutics, Inc. For: Aug 13

Thu, 13 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26916563.html

Form 8-K MiNK Therapeutics, Inc. For: Aug 13

Thu, 13 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26916563.html

MiNK Therapeutics reports Q2 2026 results and Phase 2 trial data

Thu, 13 Aug 2026 07:30:17 -0400

MiNK Therapeutics (NASDAQ: INKT) reported a net loss of $3.1 million, or $0.62 per share, for the second quarter ended June 30, 2026, down from a net loss of $4.2 million, or $1.06 per share, in the same period a year earlier, according to a company press release.

Cash and cash equivalents stood at $8.8 million as of June 30, 2026, compared with $13.4 million at December 31, 2025. Cash used in operations was $2.1 million for the quarter, up from $1.6 million in the second quarter of 2025.

The company also reported early observations from its randomized Phase 2 trial of

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Thu, 13 Aug 2026 07:30:00 -0400

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support
Clinical recovery and biologic readouts moved in the same direction; serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery and tissue repair; no major serious adverse events were attributed to agenT-797
Launched international paid named-patient access program established for physicians to request access to agenT-797, subject to per-patient regulatory authorization; building cross-border infrastructure and access

NEW YORK, Aug.

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Thu, 13 Aug 2026 07:30:00 -0400

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support
Clinical recovery and biologic readouts moved in the same direction; serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery and tissue repair; no major serious adverse events were attributed to agenT-797
Launched international paid named-patient access program established for physicians to request access to agenT-797, subject to per-patient regulatory authorization; building cross-border infrastructure and access

NEW YORK, Aug.

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026.

The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK’s off-the-shelf allogeneic iNKT cell

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Thu, 06 Aug 2026 08:19:00 -0400

Agenus posts Q2 revenue of $34.5M, plans Phase 3 colon cancer trial